collection
https://read.qxmd.com/read/28076964/trigeminal-neuralgia-diagnosis-and-treatment
#21
REVIEW
Stine Maarbjerg, Giulia Di Stefano, Lars Bendtsen, Giorgio Cruccu
Introduction Trigeminal neuralgia (TN) is characterized by touch-evoked unilateral brief shock-like paroxysmal pain in one or more divisions of the trigeminal nerve. In addition to the paroxysmal pain, some patients also have continuous pain. TN is divided into classical TN (CTN) and secondary TN (STN). Etiology and pathophysiology Demyelination of primary sensory trigeminal afferents in the root entry zone is the predominant pathophysiological mechanism. Most likely, demyelination paves the way for generation of ectopic impulses and ephaptic crosstalk...
June 2017: Cephalalgia: An International Journal of Headache
https://read.qxmd.com/read/28065687/restless-legs-syndrome-and-cardiovascular-disease-a-research-roadmap
#22
REVIEW
Daniel J Gottlieb, Virend K Somers, Naresh M Punjabi, John W Winkelman
In this paper, we first critically appraise the epidemiologic literature examining the association of restless legs syndrome (RLS) with cardiovascular disease (CVD) and then consider whether lessons learned from the study of cardiovascular consequences of other sleep disorders might inform a research agenda to examine the potential mechanisms of cardiovascular morbidity of RLS. Cross-sectional and longitudinal studies are both mixed as to whether there is a meaningful association of RLS and CVD. On the other hand, numerous cross-sectional and longitudinal observational studies have shown a strong association of obstructive sleep apnea (OSA) with CVD risk...
March 2017: Sleep Medicine
https://read.qxmd.com/read/17645916/neuroleptic-malignant-syndrome-and-serotonin-syndrome
#23
REVIEW
Koichi Nisijima, Katsutoshi Shioda, Tatsunori Iwamura
This chapter is focused on drug-induced hyperthermia with special regard to use of antipsychotics and antidepressants for the treatment of schizophrenia and major depression, respectively. Neuroleptic malignant syndrome (NMS) develops during the use of neuroleptics, whereas serotonin syndrome is caused mainly by serotoninergic antidepressants. Although both syndromes show various symptoms, hyperthermia is the main clinical manifestation. In this review we describe the historical background, clinical manifestations, diagnosis, and differential diagnosis of these two syndromes based on our observations on the experimental and clinical data...
2007: Progress in Brain Research
https://read.qxmd.com/read/28144147/neuroleptic-malignant-syndrome-an-easily-overlooked-neurologic-emergency
#24
REVIEW
Ramadhan Oruch, Ian F Pryme, Bernt A Engelsen, Anders Lund
Neuroleptic malignant syndrome is an unpredictable iatrogenic neurologic emergency condition, mainly arising as an idiosyncratic reaction to antipsychotic agent use. It is characterized by distinctive clinical features including a change in mental status, generalized rigidity, hyperpyrexia, and dysautonomia. It can be lethal if not diagnosed and treated properly. Mortality and morbidity attributed to this syndrome have recently declined markedly due to greater awareness, earlier diagnosis, and intensive care intervention...
2017: Neuropsychiatric Disease and Treatment
https://read.qxmd.com/read/20433130/prevention-recognition-and-management-of-serotonin-syndrome
#25
REVIEW
Adrienne Z Ables, Raju Nagubilli
Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity in the nervous system. It is characterized by mental status changes, autonomic instability, and neuromuscular hyperactivity. Most reported cases of serotonin syndrome are in patients using multiple serotonergic drugs or who have had considerable exposure to a single serotonin-augmenting drug. Diagnosis is made using the Hunter Serotonin Toxicity Criteria, which require the presence of one of the following classical features or groups of features: spontaneous clonus; inducible clonus with agitation or diaphoresis; ocular clonus with agitation or diaphoresis; tremor and hyperreflexia; or hypertonia, temperature above 100...
May 1, 2010: American Family Physician
https://read.qxmd.com/read/20306454/neuroleptic-malignant-syndrome-and-its-controversies
#26
REVIEW
Branimir Margetić, Branka Aukst-Margetić
PURPOSE: Neuroleptic malignant syndrome (NMS) is a rare and life threatening condition usually defined as a complication of treatment with antipsychotics characterized by severe rigidity, tremor, fever, altered mental status, autonomic dysfunction, and elevated serum creatine phosphokinase and white blood cell count. The literature on this topic is rather extensive, but many aspects related to the syndrome are thought to be controversial. The aim of this paper, written with the clinician in mind, is to summarize some of the most prominent controversies that may have importance in usual clinical practice...
May 2010: Pharmacoepidemiology and Drug Safety
https://read.qxmd.com/read/22563571/serotonin-syndrome-vs-neuroleptic-malignant-syndrome-a-contrast-of-causes-diagnoses-and-management
#27
REVIEW
Paul J Perry, Courtney A Wilborn
BACKGROUND: Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) are uncommon but potentially life-threatening adverse reactions associated with psychotropic medications. Polypharmacy and the similar presentation of SS and NMS make diagnosis of the 2 syndromes problematic. METHODS: A MEDLINE search was performed for the period 1960 to 2011 for case reports, review articles, and studies pertaining to SS and NMS. RESULTS: The majority of available literature on SS and NMS consists of case reports, case-control studies, and retrospective reviews...
May 2012: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://read.qxmd.com/read/21538518/long-term-management-issues-in-restless-legs-syndrome
#28
REVIEW
Sudhansu Chokroverty
Restless legs syndrome is a neurologic movement and sleep disorder with lifelong symptoms causing considerable morbidity. Several short-term and some long-term open-label and double-blind clinical trials have demonstrated the efficacy and safety of dopaminergic treatment in restless legs syndrome. Long-term treatment, however, is associated with the emergence of vexing long-term side effects that pose a challenge for physicians. These long-term complications can be broadly categorized as disease-related (impact on sleep and acute exacerbation of restless legs syndrome symptoms), and medication issues (augmentation, sleep attacks, impulse control disorders, addiction and dependence, site reaction, occasionally sleep apnea, fibrotic complications, and weight gain)...
July 2011: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/25578944/second-generation-antipsychotics-and-neuroleptic-malignant-syndrome-systematic-review-and-case-report-analysis
#29
REVIEW
Martino Belvederi Murri, Argentina Guaglianone, Michele Bugliani, Pietro Calcagno, Matteo Respino, Gianluca Serafini, Marco Innamorati, Maurizio Pompili, Mario Amore
BACKGROUND: Neuroleptic malignant syndrome (NMS) is a rare, severe, idiosyncratic adverse reaction to antipsychotics. Second-generation antipsychotics (SGAs) were originally assumed to be free from the risk of causing NMS, however several cases of NMS induced by SGAs (SGA-NMS) have been reported. OBJECTIVES: The aim of this study was to systematically review available studies and case reports on SGA-NMS and compare the presentation of NMS induced by different SGAs...
March 2015: Drugs in R&D
https://read.qxmd.com/read/27469512/management-of-serotonin-syndrome-and-neuroleptic-malignant-syndrome
#30
REVIEW
Linn E Katus, Steven J Frucht
Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) can present similarly and range in severity from mild to life-threatening. Although they are easily misdiagnosed, each is distinct clinically and pathophysiologically. It is important to distinguish between the two, as therapeutic options differ. An accurate and thorough medication history plus knowledge of the various clinical presentations of both syndromes are the first steps in management. After this, removing the offending agents and aggressive supportive care are crucial...
September 2016: Current Treatment Options in Neurology
https://read.qxmd.com/read/27423483/neuroleptic-malignant-syndrome
#31
REVIEW
Dominic J Pileggi, Aaron M Cook
OBJECTIVE: To review evidence for the treatment of neuroleptic malignant syndrome (NMS) and to discuss how to rechallenge patients with neuroleptics when continued pharmacotherapy for chronic psychological illness is required. DATA SOURCES: A PubMed search was conducted through March 2016 using available medical subject heading (MeSH) terms and keywords that included neuroleptic malignant syndrome, treatment, dantrolene, and bromocriptine. A manual search of article reference sections followed...
November 2016: Annals of Pharmacotherapy
https://read.qxmd.com/read/20623765/neuroleptic-malignant-syndrome-mechanisms-interactions-and-causality
#32
REVIEW
P Ken Gillman
This review focuses on new data from recent publications concerning how compounding interactions between different thermoregulatory pathways influence the development of hyperthermia and/or neuroleptic malignant syndrome (NMS), and the fundamental issue of the presumed causal role of antipsychotic drugs. The formal criteria for substantiating cause-effect relationships in medical science, established by Hill, are applied to NMS and, for comparison, also to malignant hyperthermia and serotonin toxicity. The risk of morbidities related to hyperthermia is reviewed from human and experimental data: temperatures in excess of 39...
September 15, 2010: Movement Disorders: Official Journal of the Movement Disorder Society
https://read.qxmd.com/read/27083888/vestibular-migraine-the-most-frequent-entity-of-episodic-vertigo
#33
REVIEW
Marianne Dieterich, Mark Obermann, Nese Celebisoy
Vestibular migraine (VM) is the most common cause of episodic vertigo in adults as well as in children. The diagnostic criteria of the consensus document of the International Bárány Society for Neuro-Otology and the International Headache Society (2012) combine the typical signs and symptoms of migraine with the vestibular symptoms lasting 5 min to 72 h and exclusion criteria. Although VM accounts for 7% of patients seen in dizziness clinics and 9% of patients seen in headache clinics it is still underdiagnosed...
April 2016: Journal of Neurology
https://read.qxmd.com/read/27852691/medical-management-of-intracerebral-haemorrhage
#34
REVIEW
Floris H B M Schreuder, Shoichiro Sato, Catharina J M Klijn, Craig S Anderson
The global burden of intracerebral haemorrhage (ICH) is enormous. Developing evidence-based management strategies for ICH has been hampered by its diverse aetiology, high case fatality and variable cooperative organisation of medical and surgical care. Progress is being made through the conduct of collaborative multicentre studies with the large sample sizes necessary to evaluate therapies with realistically modest treatment effects. This narrative review describes the major consequences of ICH and provides evidence-based recommendations to support decision-making in medical management...
January 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://read.qxmd.com/read/27495202/diagnosis-and-management-of-tremor
#35
REVIEW
Elan D Louis
PURPOSE OF REVIEW: Tremor, which is a rhythmic oscillation of a body part, is among the most common involuntary movements. Rhythmic oscillations may manifest in a variety of ways; as a result, a rich clinical phenomenology surrounds tremor. For this reason, diagnosing tremor disorders can be particularly challenging. The aim of this article is to provide the reader with a straightforward approach to the diagnosis and management of patients with tremor. RECENT FINDINGS: Scientific understanding of the pathophysiologic basis of tremor disorders has grown considerably in recent years with the use of a broad range of neuroimaging approaches and rigorous, controlled postmortem studies...
August 2016: Continuum: Lifelong Learning in Neurology
https://read.qxmd.com/read/27658852/pathophysiological-and-diagnostic-implications-of-cortical-dysfunction-in-als
#36
REVIEW
Nimeshan Geevasinga, Parvathi Menon, P Hande Özdinler, Matthew C Kiernan, Steve Vucic
Cortical dysfunction - specifically, the development of hyperexcitability - seems to be an early and intrinsic feature of sporadic and familial amyotrophic lateral sclerosis (ALS) phenotypes, preceding the onset of lower motor neuron dysfunction and correlating with ensuing lower motor neuron dysfunction and degeneration. In fact, cortical dysfunction could provide a pathogenic basis for ALS, with corticomotor neuronal hyperexcitability mediating motor neuron degeneration via a trans-synaptic, glutamate-mediated, excitotoxic mechanism...
November 2016: Nature Reviews. Neurology
https://read.qxmd.com/read/23649418/fibromyalgia-evolving-concepts-over-the-past-2-decades
#37
REVIEW
Mary-Ann Fitzcharles, Peter A Ste-Marie, John X Pereira
No abstract text is available yet for this article.
September 17, 2013: Canadian Medical Association Journal: CMAJ
https://read.qxmd.com/read/27637676/stroke
#38
REVIEW
Graeme J Hankey
In the past decade, the definition of stroke has been revised and major advances have been made for its treatment and prevention. For acute ischaemic stroke, the addition of endovascular thrombectomy of proximal large artery occlusion to intravenous alteplase increases functional independence for a further fifth of patients. The benefits of aspirin in preventing early recurrent ischaemic stroke are greater than previously recognised. Other strategies to prevent recurrent stroke now include direct oral anticoagulants as an alternative to warfarin for atrial fibrillation, and carotid stenting as an alternative to endarterectomy for symptomatic carotid stenosis...
February 11, 2017: Lancet
https://read.qxmd.com/read/27549763/disease-modifying-therapies-for-relapsing-multiple-sclerosis
#39
REVIEW
Dean M Wingerchuk, Brian G Weinshenker
Multiple sclerosis (MS) is a common, disabling, putatively autoimmune neurological disease with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a secondary progressive phase. Inflammatory and neurodegenerative mechanisms seem to operate in both phases, but their relative contributions and interactions are incompletely understood. Disease modifying therapies (DMTs) approved for relapsing multiple sclerosis interfere with a variety of immunological mechanisms to reduce rates of relapse, accumulation of disease burden measured by magnetic resonance imaging (MRI), and decline in neurological function over the two to three year duration of typical randomized controlled trials...
August 22, 2016: BMJ: British Medical Journal
https://read.qxmd.com/read/27526039/progressive-supranuclear-palsy-and-corticobasal-degeneration-pathophysiology-and-treatment-options
#40
REVIEW
Ruth Lamb, Jonathan D Rohrer, Andrew J Lees, Huw R Morris
There are currently no disease-modifying treatments for progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD), and no approved pharmacological or therapeutic treatments that are effective in controlling their symptoms. The use of most pharmacological treatment options are based on experience in other disorders or from non-randomized historical controls, case series, or expert opinion. Levodopa may provide some improvement in symptoms of Parkinsonism (specifically bradykinesia and rigidity) in PSP and CBD; however, evidence is conflicting and where present, benefits are often negligible and short lived...
September 2016: Current Treatment Options in Neurology
label_collection
label_collection
6916
2
3
2016-08-28 08:43:51
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.